Epigenetic Modifications Induced by Glycemic Variability

Scripps Translational Science Institute1 site in 1 countryJanuary 2013

ConditionsType I Diabetes

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Type I Diabetes
Sponsor: Scripps Translational Science Institute
Locations: 1
Primary Endpoint: Evaluate blood sugar variability in Type I diabetics for differences in epigenetic signatures between Type I diabetics with little glycemic variability as compared to those with more pronounced glycemic changes.
Status: Withdrawn
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This research is being done to find out if significant changes in blood glucose cause bad outcomes in patients with diabetes.

Registry

clinicaltrials.gov

Start Date

January 2013

End Date

January 2014

Last Updated

12 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Scripps Translational Science Institute

Responsible Party

Principal Investigator

Eric Topol, MD

Director

Scripps Translational Science Institute

Eligibility Criteria

Inclusion Criteria

•18-65 years old
•Diagnosis of Type I diabetes
•Willing to wear continuous blood glucose monitor as specified in protocol

Exclusion Criteria

•Pregnant or planning to become pregnant during the study
•Healthy control group Inclusion:
•18-65 years old
•Willing to wear continuous blood glucose monitor as specified in protocol
•Pregnant or planning to become pregnant during the study
•Diagnosis of Type I or II Diabetes

Outcomes

Primary Outcomes

Evaluate blood sugar variability in Type I diabetics for differences in epigenetic signatures between Type I diabetics with little glycemic variability as compared to those with more pronounced glycemic changes.

Time Frame: 7 days